M.B.A, CEO, Mission Bio
Charlie Silver is CEO and co-founder of Mission Bio where he leads a team dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. Charlie has dedicated his career to commercializing next-generation hardware technology and scientific instrumentation at emerging ventures in healthcare and semiconductor. Prior to Mission Bio, he led engineering at Novelx (acquired by Agilent) and then served in R&D and marketing at Agilent. Charlie received a joint MBA from UC Berkeley and Columbia University, an MS in physics from UW Madison, and a BA in physics from Columbia University.
Scalable Single-Cell DNA Analysis for Precision Medicine
With NGS costs dropping, large-scale, single-cell heterogeneity studies now offer great promise to move precision medicine forward in complex diseases characterized by clonally diverse cell populations. Scalable and highly sensitive single-cell DNA analysis enables insights missed by conventional bulk sequencing to impact patient stratification, therapy selection, and disease monitoring.